Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab for Prevention of Chronic GvHD Following alloHCT
NCT03207958Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- May 2018
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of belimumab in graft-versus-host disease (GVHD), sponsored by Washington University School of Medicine. Primary endpoint: Number of Participants Who Experience Each Adverse Event up to 229 days. Started May 2018; status: completed.
02
Drugs
belimumab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03207958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03207958.